No 02 2014

Per Uhlén, professor of cell signaling at Karolinska Institutet (KI), receives the 2026 Lennart Nilsson Award today at KI's professorial installation ceremony in Aula Medica. He is honored for developing advanced microscopy methods that visualize the fundamental processes of life.

Finnish Orion Pharma has signed an agreement with Qilu Pharma Europe for a pembrolizumab biosimilar for the European market. A day earlier, it dosed the first patient with ODM-216, its first biologic drug candidate to reach clinical testing.

Bavarian Nordic has raised its full-year 2026 guidance for the third time this year. It now expects revenue of about DKK 6,100 million, up from about DKK 5,700 million, driven by higher sales of rabies vaccines, mainly in the US.

Norwegian Prime Minister Jonas Gahr Støre will officially open Thor Medical's AlphaOne production facility at Herøya Industrial Park on October 19. The Oslo-based company supplies high-purity alpha-emitting isotopes to the radiopharmaceutical industry.

Aiforia has announced a commercial agreement with PathAI, a member of the Roche Group.

Henri B. Kagan and Kenso Soai are awarded the Nobel Prize in Chemistry 2026 for discovering how chemical reactions can produce only one of two mirror-image molecules. Their work shows how this kind of asymmetry can arise, and has been decisive for chemists designing reactions to make pharmaceuticals.

After twelve years leading Norway's oldest health cluster, Ketil Widerberg is leaving Oslo Cancer Cluster to head an AI initiative in healthcare at Oslo University Hospital.